Merck’s HCV Combo Will Test FDA’s ‘Breakthrough’ Rescission Process
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency cites availability of other recently approved therapies in notifying Merck of intent to rescind the designation for grazoprevir/elbasvir in hepatitis C. Sponsor will seek a meeting with FDA to make its case for retaining breakthrough status.